Floatz logo

[177lu]lu-dpi-4452

Indeterminate Renal Mass (IDRM)

ITM Oncologics GmbHradiopharmaceuticalPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Indeterminate Renal Mass (IDRM) cohort.

Asset / SponsorPhaseRating
Axitinib
Pfizer
Phase 3BB
Ipilimumab
Pfizer
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Inno-206
Merck Sharp & Dohme LLC
Phase 2BB
Sorafenib
Pfizer
Phase 3B

View all 50 →

Same molecule, other indications

[177lu]lu-dpi-4452 is also rated in:

nonpapillary renal cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
infiltrating bladder urothelial carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
head and neck cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →